Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. ENOV
4. AON
5. AZN
6. BLSM
7. GPRO
8. KRMN
9. SPGI
10. GRMN

Go back to Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Novavax (NVAX) PT Lowered to $14 at BofA Securities 'to reflect delays in phase 3 CIC/standalone flu trial'

October 16, 2024 11:43 AM EDT

BofA Securities analyst Alec Stranahan lowered the price target on Novavax (NASDAQ: NVAX) to $14.00 (from $17.00) while maintaining a Neutral rating.

The analyst comments "NVAX shares are trading down (-17.2%; NBI: +0.60%) after a clinical hold was placed on the IND for the companys... More